Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells

• Markus Hecht ,

  * E-mail: Markus.Hecht@uk-erlangen.de

  Affiliation Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany

  ⨯
• Sonja Erber,

  Affiliation Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany

  ⨯
• Thomas Harrer,

  Affiliation Department of Internal Medicine 3, University Hospital Erlangen, Erlangen, Germany

  ⨯
• Hartwig Klinker,

  Affiliation Department of Internal Medicine 2, University Hospital Würzburg, Würzburg, Germany

  ⨯
• Thomas Roth,

  Affiliation Central Laboratory, University Hospital Erlangen, Erlangen, Germany

  ⨯
• Hans Parsch,

  Affiliation Central Laboratory, University Hospital Erlangen, Erlangen, Germany

  ⨯
• Nora Fiebig,

  Affiliation Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany

  ⨯
• Rainer Fietkau,

  Affiliation Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany

  ⨯
• Luitpold V. Distel

  Affiliation Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany

  ⨯